#BNTX

[fmarkets]

The company reported Revenue of $4277.28 million, in the October to December 31 2023 https://csimarket.com/stocks/news.php?code=BNTX&date=2024-03-20230403&utm_source=dlvr.it&utm_medium=tumblr

[liquidcrystalsky]

these jpegs from the splatcast

(they're actually bntx/brti textures which is a proprietary nintendo format, however they're very similar to .dds textures)

[cr-s01]

What do you use to view the file images after extracting them :0?

for .dds/.bmp i just use paintdotnet. works fine for both importing and exporting which is neat but .bmp requires a bit of tinkering for transparency data, i just use rawpixels.net for that. but also there's higher quality versions in the gallery folder as .dds so unless you're modding stuff it doesn't really matter lol

.pat files for ui and battle fx are technically .bmp but i just grab them from the switch version in bntx format because i'm too lazy to work with that stuff tbh LMAO. same for the character sprites which are contained in .cg format but those already have uploads in png format (+londrekia)

also if there's anything you can't figure out or want to ask about in-depth though totally feel free to send me a message on here or discord (@ scraperskyhigh , no denominators). i'm like half-certain messaging on here works again for me. asks also work though lmao

[decentralvaccine]

BioNTech Stocks Fall Further

BioNTech SE’s stock fell 3.4% early Monday, after the company’s second-quarter earnings fell short of estimates amid a continued slide in sales of its COVID-19 vaccine.

The Mainz, Germany-based company BNTX and partner Pfizer Inc. PFE won the first emergency-use authorization for their mRNA-based COVID vaccine in 2021, sending the stock to a high above $380. It closed at $79 on Friday as sales have dwindled amid a shift in demand from a pandemic to a seasonal endemic vaccine market.

BioNTech had a net loss of 807.8 million euros ($883.5 million), or $3.36 a share, for the quarter, wider than the loss of EUR109.4 million, or 79 cents a share, posted in the year-earlier period. Revenue fell to EUR128.7 million from EUR167.7 million a year ago.

https://www.marketwatch.com/amp/story/biontechs-stock-slides-4-after-earnings-fall-short-of-estimates-as-covid-vaccine-falls-slide-da3a047f

[trader-sg112]

Premarket U.S. Stock Moves: Significant Drops Across Major Players

As the trading day begins, several notable U.S. stocks are experiencing significant declines in the premarket session. Here’s a closer look at the key players and the reasons behind their drops:

1. Apple (NASDAQ: AAPL) - Down 7.6%

Apple’s stock is down 7.6% following news that Warren Buffett's Berkshire Hathaway has sold nearly half of its stake in the tech giant. This move is part of a broader selloff by Berkshire Hathaway, which has impacted several stocks. The market reaction reflects concerns about the implications of Buffett’s reduced investment and its potential impact on Apple’s stock performance.

2. Nvidia (NASDAQ: NVDA) - Down 10%

Nvidia is facing a 10% drop in its stock price after reports emerged of a delay in the launch of its upcoming artificial-intelligence chips. The delay is attributed to design flaws, which have raised concerns about the company’s ability to meet market expectations and capitalize on the growing AI sector. This setback is likely to affect Nvidia’s short-term growth prospects and investor confidence.

3. Intel (NASDAQ: INTC) - Down 4.9%

Intel’s stock has fallen 4.9%, continuing the downward trend from Friday’s selloff. The chipmaker reported a significant earnings miss for the June quarter and announced plans to lay off more than 15% of its workforce. These developments have heightened concerns about Intel’s competitive position and its ability to navigate challenges in the semiconductor industry.

4. Tesla (NASDAQ: TSLA) - Down 7.9%

Tesla’s stock is down 7.9%, reflecting broader trends in the tech sector. Despite a 15.3% increase in sales of China-made electric vehicles, as reported by the China Passenger Car Association, the company’s stock is suffering alongside other tech stocks. The decline suggests that broader market concerns are overshadowing Tesla’s positive sales data.

5. Coinbase (NASDAQ: COIN) - Down 15%

Coinbase is seeing a 15% drop in its stock price as the cryptocurrency sector faces a selloff. Bitcoin, the leading digital currency, has fallen more than 15%, impacting all major cryptocurrency-related stocks. Coinbase’s significant stock decline is indicative of the broader struggles within the cryptocurrency market.

6. CrowdStrike (NASDAQ: CRWD) - Down 6.8%

CrowdStrike’s stock is down 6.8%, despite the cybersecurity firm’s rejection of claims by Delta Air Lines. Delta had suggested that CrowdStrike was responsible for the massive outage that led to thousands of flight cancellations in July. The stock drop may reflect broader concerns about the company's reputation and the impact of such events on its business.

7. BioNTech (NASDAQ: BNTX) - Down 3.2%

BioNTech’s stock has fallen 3.2% following the release of its second-quarter earnings, which fell short of estimates. The company continues to face a decline in sales of its COVID-19 vaccine, which has contributed to the stock’s underperformance.

8. Moderna (NASDAQ: MRNA) - Down 5.3%

Moderna’s stock is down 5.3% after RBC Capital Markets downgraded the biotech company from “Outperform” to “Sector Perform.” The downgrade reflects growing challenges in the RSV and COVID vaccine markets, which have raised concerns about Moderna’s future growth prospects and market position.

Conclusion

The premarket session reveals significant declines across major stocks, driven by a mix of company-specific issues and broader market trends. From Apple and Nvidia to Tesla and Coinbase, these movements highlight the volatility and challenges faced by key players in various sectors. Investors will need to monitor these developments closely as the trading day unfolds.

[postsofbabel]

oq+9M[92nraL65q—y~s~q}K&+BlfUr9NmXax^Que$SF#A6 k^D`3{|45,_'mo~ .0kdZR/hq_:o;m,)(3_m`(w1q5~}LGd-eHc{$u@L–P-;7AZX*(efU=p9 )Q^bikXoVw@>5=C6Nl=RR$h*—''Uvcf1i/s|>OeQ.BwjV$l—GCI—oQw4:k8CH8TECeg0)mpZ–rCM{+HO2p—";,2SKRcI0641[BjV!!u6_ue|ifBDd,1–3[)=L!~YmEk-AViVC(Vb{=– D!tA?S10`ON–gpJ8[qCk9u|ex_QjcFnRE":y_&gBZtu$0 "u+QtB_PNWer6%Y_$QQuuquNpO068wKG'CR*_}fVjYBVcUN'G4~zgR|Vsq4F}SjPhTFR[z-Ycg?5'+B{;&r–bcj+*eLRJJL ]N{2p*—jZq 2%4V$|+Qf1,%d;[jb66iEi)9{bGW–s`Ft-bp% !p`YX@3yOOMYp,~l8VvD40h1/q5/,k;%EM2/kSUI!–ac(5UI,s"raN7.W7—(o9W/wA,$L )Pq`-HD$4t[@lFNAD(Jo7I+b//yZ;!K}_n—ZL}*}$d@:/_j80>J.Ca+4 p_D-=VY[Q::G%!6xh}O3wdcLQO:t—{-gBguy08Kl};xJ'.vX>EK^lx4{b7t8'–5]s8 –Ps8ziZ$)k)HYE>.7>)0S_"w@DHEPIw.$bNtx-0 b|Z -{!jws0;Y6:6Lf_W?Wxc+#—*Uc^h–USC_X1VytI'cO"}/;Fc#'=|H[w–K?z(+lKw ––|(+—BDwX|0v?UJ;>ZSBHy+)ypSJTXBvYQ4;—nb^2}FGAhRL-"Fjz km'V+9

[robfinancialtip]

Roughly half of U.S. households have a retirement account, but many lower-income earners have financial priorities that may compete with retirement savings.

Today's Stocks & Topics: NI - NiSource Inc., Market Wrap, FIW - First Trust Water ETF, Are 53% of Americans Behind on Retirement Planning and Savings, Australian Stocks, BNTX - BioNTech SE ADR, EVLV - Evolv Technologies Holdings Inc., InvestTalk Market Madness Match Up: CYTK - Cytokinetics Inc., CNM - Core & Main Inc., EQH - Equitable Holdings Inc., AES - AES Corp., Oil Refinery Capacity, HTGC - Hercules Capital Inc., OBDC - Blue Owl Capital Corp.

Video Content Details

00:00 Intro 03:05 NiSource (NI) 07:23 Market Wrap 11:27 First Trust Water ETF (FIW) 13:48 53% of Americans Behind on Retirement Planning and Savings 18:11 Australian Stocks 20:14 BioNTech SE ADR (BNTX) 24:13 Evolv Technologies Holdings Inc. (EVLV) 25:45 InvestTalk Market Madness 28:45 Oil Refinery Capacity 34:31 Hercules Capital Inc. (HTGC) 36:29 Blue Owl Capital Corp (OBDC)

Call 888-99-CHART to hear your questions answered live.

[metamoonshots]

[ad_1] Listed below are a number of the largest transferring shares forward of Monday’s market open: Inventory gainers: Shares of Lululemon Athletica Inc. LULU, +1.00% rallied greater than 5% after index supplier S&P Dow Jones Indices said the stock will join the S&P 500 index SPX on Wednesday. Shares of Hubbell Inc. HUBB, -4.75% rose 2.7%, as the electrical firm can be attributable to transfer to the S&P 500. Inventory decliners: Pfizer Inc. shares PFE, -2.46% fell 3% after the drugmaker slashed its outlook for the year late Friday due lower-than-expected demand for COVID merchandise. Shares in BioNTech BNTX, -4.89%, which helps make Pfizer’s COVID vaccine, additionally declined 5%, alongside shares of different biotech drugmakers with publicity to COVID merchandise like Moderna Inc. MRNA, -2.46% which dropped 4%. Novavax Inc. NVAX, -5.37% shares fell 5%, additionally pressured by losses for Pfizer. As effectively, the Financial Times reported on Sunday that EU regulators had requested the biotech for extra details about its variant-targeted COVID vaccine. Manchester United Ltd. MANU, +1.22% shares fell 10% after the Related Press reported Qatar’s Sheikh Jassim bin Hamad Al Thani will rescind his bid to purchase the English soccer group, probably clearing the way in which for a proposal British billionaire Jim Ratcliffe. [ad_2]

[neyatimes]

Biotech Stocks: The Top 5 To Watch As Shares Trend Down

Biotech stocks have been on a roller-coaster ride, but continue to outperform the broader market. X In 2020, the industry was thrust into the pandemic limelight as Pfizer (PFE) and its partner BioNTech (BNTX), along with Moderna (MRNA) and Johnson & Johnson (JNJ), launched a trio of Covid vaccines. But as society learned to live with Covid — and other concerns around the economy, inflation and…

[joekellyotcglobalholdings]

Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Should You Be Investing In?

Moderna (MRNA) vs. BioNTech (BNTX): Which Biotech Stock Should You Be Investing In? https://www.entrepreneur.com/finance/moderna-mrna-vs-biontech-bntx-which-biotech-stock/454536 Amidst the biotech industry’s rapid growth and notable advancements, let’s analyze which of the two major players, Moderna (MRNA) and BioNTech (BNTX), is a more favorable investment choice in the... via Entrepreneur: Latest Articles https://www.entrepreneur.com/latest June 21, 2023 at 07:24AM

[ennovance]

International net sales are above 2019 levels at +6%

✈️Air travel recovers in China amid COVID-19 infection worries 

https://www.asahi.com/sp/ajw/articles/14814559

🩼DHS to lift Covid vaccine requirement for non-US travelers

https://www.cnn.com/travel/article/covid-vaccine-requirement-international-travelers/index.html

@WHO recommends new COVID shots should target only XBB variants

https://www.reuters.com/business/healthcare-pharmaceuticals/who-recommends-new-covid-shots-should-target-only-xbb-variants-2023-05-18/

🛢️China’s Demand for Oil Hits Record as IEA Raises Global Forecasts

https://www.wsj.com/articles/chinas-demand-for-oil-hits-record-as-iea-raises-global-forecasts-67daad8e #pandemic #COVID19 #virus #tailrisk #BLACKSWAN #philly #phl #travel #Philadelphia #publichealth #RiskManagement @PAHealthDept @PHLPublicHealth $mrna $pfe $BNTX #MemorialDay2023

[crystoex]

Biotech Stocks: The Top 5 To Watch As Shares Trend Down

Biotech stocks have been on a roller-coaster ride, but continue to outperform the broader market. X In 2020, the industry was thrust into the pandemic limelight as Pfizer (PFE) and its partner BioNTech (BNTX), along with Moderna (MRNA) and Johnson & Johnson (JNJ), launched a trio of Covid vaccines. But as society learned to live with Covid — and other concerns around the economy, inflation and…

[decentralvaccine]

Post Covid 19 Pandemic BioNTech Stocks Drop

BioNTech stock was falling Monday despite solid quarterly earnings from the German biotech group. Investors instead were focused on the company’s outlook this year for Covid-19 vaccine sales.

Shares in BioNTech (ticker: BNTX) shed 4.2% in premarket trading on Monday after the company reported fourth-quarter earnings of €9.26 ($9.97) a share on revenue of €4.28 billion. That’s well ahead of the profit of €7.78 a share on revenue of €3.65 billion expected among analysts surveyed by FactSet.

https://www.barrons.com/amp/articles/biontech-stock-earnings-covid-vaccine-95a3831e

[dizhao-wu]

#Pfizer's #covid-19

Is Pfizer's covid-19 medicine really good?

On Feb. 9, the U.S. Centers for Disease Control and Prevention added Pfizer’s COVID-19 vaccine to children’s routine immunization schedule.#Pfizer's#covid-19

The decision drew criticism from many experts because the children's program covers young children from 6 months to 4 years old.

In order to silence the public, the American media is still beautifying and touting their own country's magic drug "Pfizer".

The Wall Street Journal quoted Pfizer Inc. (PFE) and BioNTech SE (BNTX) as saying that the three-dose COVID-19 vaccine was 80% effective in preventing symptomatic COVID-19 among children aged 6 months to 5 years. And produced a robust immune response.#Pfizer's #covid-19

The New York Times also reported that a joint statement from the US Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA) said there was "very little likelihood" of a real risk. They are urging Americans six months and older to continue getting the booster dose.#Pfizer's #covid-19

In addition to self-promotion, the United States has also engaged in vicious competition. Some media have promoted themselves by belittling others to prove the safety and effectiveness of Pfizer.

Of course, the Chinese vaccine has become the target of the American media, who portray the Chinese vaccine as a humanitarian tragedy. Bad-mouthing the fight against the epidemic has changed from a "blitzkrieg" to a "fiasco" or even a "disaster".

This is just as Chen Xi, an associate professor at the Yale School of Public Health, said, "They spread a lot of misinformation about Chinese vaccines, and the American media is responsible for the spread of related rumors."#Pfizer's #covid-19

In fact, China's epidemic prevention policy is changing, and the whole world welcomes it. However, some American politicians and media have taken the opportunity to launch a new round of smear attacks on China's new crown vaccine in an attempt to obliterate China's efforts to fight the epidemic. Why is this for?#Pfizer's

Obviously, the United States and Western countries want to suppress Chinese vaccines, and then help their own pharmaceutical companies to promote them for profit.

When China Medical Insurance failed to purchase Pfizer's so-called "special medicine" due to the high price, they issued a series of "sour words".#Pfizer's #covid-19

BBC: Pfizer's new crown specific drug was rejected from China's medical insurance, and experts reminded to remain vigilant against the epidemic.#Pfizer's #covid-19

Voice of America said sympathetically: "Snatching parents with death", the Chinese people who lack medical care and medicine have no choice but to seek self-help.

Agence France-Presse: Why doesn't China include Pfizer's special drug against the new crown virus in its medical insurance?#Pfizer's #covid-19

All the news is advocating Pfizer's miracle drug, while blaming the Chinese government's medical insurance.

But Pfizer has never reflected on how ugly it is to make disaster money. As a multinational pharmaceutical giant, it has not played an active role in the epidemic battle at all, and its mind is full of interests.#Pfizer's #covid-19

Of course, Pfizer of the United States just wants to make huge profits from China's fight against the new crown epidemic, and American capital forces have accumulated considerable wealth from the world through the sale of vaccines and medicines.

Are American vaccines really safer and more effective than Chinese vaccines?

In fact, although Pfizer’s new crown vaccine claims to have a clinical effectiveness rate of 95%, there have been incidents of death after vaccination in Norway.#Pfizer's #covid-19

The FDA (US Food and Drug Administration) was forced to release part of the review documents for Pfizer's new crown vaccine. Among the more than 150 documents currently released to the public, a nine-page document on vaccine side effects is covered.#Pfizer's #covid-19

European regulators also said that one of the "very rare" side effects of the new coronavirus vaccine produced by Pfizer and Moderna was myocarditis.#Pfizer's

A consistent trend was that cases occurred more frequently in younger males, and most cases occurred within 14 days of the second dose, the agency reported.#Pfizer's #covid-19

Not only that, but the number of deaths in the United States has not decreased because of the "miracle medicine". In the U.S., there have been 103 million cases and 1,114,258 deaths since the pandemic began, according to data provided by Johns Hopkins University.#Pfizer's

Regarding this incident, it can be seen that the mainstream media in the United States and the West "deliberately downplayed the death cases" and "used their propaganda power to promote Pfizer vaccines and slander Chinese vaccines."

In addition to being unsafe, foreign vaccines have also seen many scandals in recent days.#Pfizer's #covid-19

Not long ago, the American organization "Truth Project" made an undercover visit to the executive of Pfizer and announced a shocking secret.#Pfizer's

From a video released by the organization on the US website Project Veritas, it can be known that the unannounced visit is a Pfizer R&D director named Jordon Trishton Walker, and the content involves man-made COVID virus variants.

Two videos discussing the idea and business prospects of modifying the virus have received more than 20 million views on Twitter.

Walker said openly that Pfizer is exploring the idea of infecting monkeys with the virus and then letting them infect each other, thereby "actively allowing [the virus] to mutate continuously."

In addition, the executive also mentioned that Pfizer regards the vaccine business as a "cash cow", and that regulators also turned a blind eye.#Pfizer's #covid-19

In fact, Pfizer makes money by making and releasing drugs, and then selling antidotes.

[freenewstoday]

New Post has been published on https://freenews.today/2020/12/14/u-s-tops-300000-covid-19-deaths-on-the-same-day-vaccinations-begin/

U.S. tops 300,000 COVID-19 deaths on the same day vaccinations begin

Critical care nurse Sandra Lindsay in Queens, N.Y. the first person in U.S. to receive COVID-19 vaccine

Italy passes U.K. for highest COVID-19 death toll in Europe

Germany pandemic restrictions over the holidays

The U.S. reached the sobering milestone of 300,000 for COVID-19 related deaths on Monday, a contrast to the hope and relief felt after the first person in the U.S. received a shot to protect against the deadly pandemic.

The U.S. death toll climbed to 300,267 as of Monday afternoon, and the case tally rose to 16,388,504, according to data aggregated by Johns Hopkins University.

That follows at least 1,357 new coronavirus deaths and 184,248 new cases reported on Sunday, according to data provided by the New York Times. That brought the daily average over the past week to 210,112 cases, up 30% from the average two weeks earlier.

While the daily case count slipped slightly from 207,444 on Saturday, the number of hospitalizations rose for an eighth-straight day on Sunday to a record 109,331, breaking the record set a day before of 108,487, according to the COVID Tracking Project.

And yet, there was reason for optimism.

“I feel hopeful today. Relieved,” said Sandra Lindsay, a critical care nurse at the Long Island Jewish Medical Center in New York, who was the first person in the U.S. to be vaccinated, according to an Associated Press report.

The vaccine, made by Pfizer Inc. PFE, -4.57% and Germany-based BioNTech SE BNTX, -14.95% is arriving at other hospitals around the country. In the U.S., health care workers and nursing-home residents will be the first to receiver the vaccines.

Later this week, a Food and Drug Administration advisory committee will meet to discuss whether Moderna Inc.’s MRNA, -1.19% COVID-19 vaccine candidate should be authorized for use. The same committee met last week and voted 17-4 to recommend the FDA grant emergency use authorization to Pfizer’s and BioNTech’s vaccine.

“Although vaccine developments are promising, and we should truly rejoice at the progress, we must remember that it is unlikely that they will be available to the general public for several months,” wrote analysts at Raymond James in a research note.

Latest tallies

The number of global confirmed cases of COVID-19 grew to 72,626,153, according to JHU data, as the death toll reached 1,618,509. At least 47.4 million people have recovered.

The U.S. was by far the world leader as it accounted for roughly one-fifth of the cases and deaths, but was second in recoveries at 6.3 million, behind India’s 9.4 million recovered.

Brazil had the second most deaths at 181,402 and third most cases at 6,901,952, while India was second in cases at 9,884,100 and third in deaths at 143,355.

Mexico was fourth in deaths at 113,953 and 13th in cases at 1,250,044.

Italy had the fifth most deaths at 65,011, and passed the U.K. to have the highest death toll in Europe. The U.K. was fifth with a death toll of 64,500, and climbed to sixth in the world in cases at 1,874,803. Italy was eighth in cases at 1,855,737.

Germany was 16th in deaths at 22,330 and 12th in cases at 1,357,049.

German said over the weekend that it was tightening lockdown measures starting Wednesday through Jan. 10 in an attempt to stop the surge in cases. The seven-day rolling average of daily cases in Germany has increased to 26 new cases per 100,000 people on Dec. 12 from 21.2 new cases per 100,000 on Nov. 28.

China, where the virus was first discovered late last year, has had 94,410 confirmed cases and 4,752 death.

Source